Ana
Fernández Montes
![Foto de Ana](/img/nophoto.png)
![Foto de Hospital Universitari de Bellvitge](/img/noimage_org.png)
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (19)
2024
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
SEOM 2022 clinical guidelines
Clinical and Translational Oncology
-
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
Oncologist, Vol. 28, Núm. 10, pp. E902-E909
2022
-
SEOM clinical guidelines (2021)
Clinical and Translational Oncology
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2020
-
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750
2018
-
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264
2017
-
Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction
Clinical Respiratory Journal, Vol. 11, Núm. 6, pp. 859-866
2014
-
Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1
BMC Pulmonary Medicine, Vol. 14, Núm. 1
2006
-
Does induction chemotherapy still have a role in larynx preservation strategies? The experience of institut catala d'oncologia in stage III larynx carcinoma
Laryngoscope, Vol. 116, Núm. 9, pp. 1651-1656
2004
-
Treatment of malignant superior vena cava syndrome by endovascular stent insertion: Experience on 52 patients with lung cancer
Lung Cancer, Vol. 43, Núm. 2, pp. 209-214
2000
-
Meningeal carcinomatosis as a cause of partially reversible blindness
Clinical and Translational Oncology
1997
-
CDC group IV c-2 infection in a stem cell transplant recipient
Bone Marrow Transplantation, Vol. 20, Núm. 11, pp. 1005-1006